公开(公告)号：US12102608B2

公开(公告)日：2024-10-01

申请号：US17825260

申请日：2022-05-26

申请人： EPITECH GROUP S.P.A.

发明人： Francesco Della Valle ,  Maria Federica Della Valle ,  Gabriele Marcolongo ,  Chiara Gomiero

IPC分类号： A61K31/164 ,  A23L33/115

CPC分类号： A61K31/164 ,  A23L33/115

摘要： A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages):
















oleoylethanolamide (OEA) C18:1
60-65% 



palmitoylethanolamide (PEA) C16:0
5-20%



linoleylethanolamide (LEA) C18:2
5-20%



stearoylethanolamide (SEA) C18:0
 1-2%



palmitoylethanolamide (POEA) C16:1
0.1-0.8% 



myristoylethanolamide (MEA) C14:0
0.02-0.15%  



mixture of glycerides
 4-6%



glycerol
 6-8%.










A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.

公开(公告)号：US11491122B2

公开(公告)日：2022-11-08

申请号：US16374912

申请日：2019-04-04

申请人： Epitech Group S.p.A.

发明人： Maria Federica Della Valle ,  Francesco Della Valle ,  Vincenzo Di Marzo ,  Stefania Petrosino ,  Barbara Costa ,  Gabriele Marcolongo ,  Daniele Grassi

IPC分类号： A61K31/16 ,  A61K45/06 ,  A61K31/164 ,  A61K31/201 ,  A61K31/421 ,  A61K31/728 ,  A61K36/062 ,  A61K36/28

摘要： Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.

公开(公告)号：US20220304956A1

公开(公告)日：2022-09-29

申请号：US17665894

申请日：2022-02-07

申请人： Epitech Group S.p.A.

发明人： Francesco DELLA VALLE ,  Maria Federica DELLA VALLE ,  Gabriele MARCOLONGO ,  Giuliano CLAPS ,  Chiara GOMIERO ,  Vito SAFINA ,  Annalisa NOCE ,  Salvatore CUZZOCREA ,  Giuseppe ESPOSITO

IPC分类号： A61K31/164 ,  A61K9/14 ,  A61P31/14 ,  A61K9/20 ,  A61K9/16 ,  A61K9/48

摘要： The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

公开(公告)号：US20230381121A1

公开(公告)日：2023-11-30

申请号：US18303789

申请日：2023-04-20

申请人： EPITECH GROUP S.P.A.

发明人： Raffaella DELLA VALLE ,  Maria Federica DELLA VALLE ,  Gabriele MARCOLONGO ,  Chiara GOMIERO ,  Salvatore CUZZOCREA ,  Antonio CALIGNANO ,  Claudia CRISTIANO

IPC分类号： A61K31/164 ,  A61K31/4045 ,  A61K31/405 ,  A61P25/00 ,  A61K9/14

CPC分类号： A61K31/164 ,  A61K31/4045 ,  A61K31/405 ,  A61P25/00 ,  A61K9/141

摘要： The present invention relates to the use of N-palmitoylethanolamide (PEA) in association with melatonin or natural precursors thereof in the treatment of autism spectrum disorder (ASD) and other neurobehavioral disorders similarly accompanied by restlessness, irritability, sleep disorders, and potentially stereotypies.
In particular, the present invention relates to the use of PEA in association with melatonin in the treatment of ASD, wherein the palmitoylethanolamide is administered in association with melatonin or tryptophan (TRP) or 5-hydroxytriptophan (5H-TRP), wherein said administration is separate, combined or simultaneous.

公开(公告)号：US20220304954A1

公开(公告)日：2022-09-29

申请号：US17213856

申请日：2021-03-26

申请人： Epitech Group S.p.A.

发明人： Francesco Della Valle ,  Maria Federica Della Valle ,  Gabriele Marcolongo ,  Giuliano Claps ,  Chiara Gomiero ,  Vito Safina

IPC分类号： A61K31/16 ,  A23L33/12

摘要： The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

公开(公告)号：US20240315990A1

公开(公告)日：2024-09-26

申请号：US18736787

申请日：2024-06-07

申请人： Epitech Group S.P.A.

发明人： Francesco Della Valle ,  Maria Federica Della Valle ,  Salvatore Cuzzocrea

IPC分类号： A61K31/16 ,  A61K31/164 ,  A61K31/728

CPC分类号： A61K31/16 ,  A61K31/164 ,  A61K31/728

摘要： Described herein are pharmaceutical compositions containing Adelmidrol. In particular, the Adelmidrol is used in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals, more particularly in the treatment of articular chondropathies of mechanical, toxic, iatrogenic, degenerative origin, or associated with inflammatory phenomena mainly related to organs and tissues not belonging to the osteoarticular system; fibrogenesis of the articular cartilages; chronic inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis; Irritable Bowel Syndrome (IBS); diseases characterized by an abnormal fibrosis of the connective tissue, such as systemic sclerosis, particularly of the skin and lung; eye disorders characterized by angiogenesis, fibrosis, inflammation and oxidative stress.

公开(公告)号：US20220409570A1

公开(公告)日：2022-12-29

申请号：US17836902

申请日：2022-06-09

申请人： EPITECH GROUP S.P.A.

发明人： Francesco DELLA VALLE ,  Maria Federica DELLA VALLE ,  Chiara GOMIERO ,  Gabriele MARCOLONGO ,  Salvatore CUZZOCREA

IPC分类号： A61K31/352 ,  A61K31/164 ,  A61K31/7034 ,  A61K9/14 ,  A61P13/08 ,  A61K9/20 ,  A61K9/24 ,  A61K9/02 ,  A23L33/105 ,  A23L33/12 ,  A23K20/158

摘要： A composition is based on N-palmitoyl-ethanolamide and Baicalein in the co-micronized form. The includes a mixture of palmitoyl-ethanolamide (PEA) and Baicalein in co-micronized form. The composition is usable for treating benign prostatic hyperplasia.

公开(公告)号：US20220378725A1

公开(公告)日：2022-12-01

申请号：US17825260

申请日：2022-05-26

申请人： EPITECH GROUP S.P.A.

发明人： Francesco DELLA VALLE ,  Maria Federica DELLA VALLE ,  Gabriele MARCOLONGO ,  Chiara GOMIERO

IPC分类号： A61K31/164 ,  A23L33/115

摘要： A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages): oleoylethanolamide (OEA) C18:1
60-65%  palmitoylethanolamide (PEA) C16:0
5-20% linoleylethanolamide (LEA) C18:2
5-20% stearoylethanolamide (SEA) C18:0
 1-2% palmitoylethanolamide (POEA) C16:1
0.1-0.8%  myristoylethanolamide (MEA) C14:0
0.02-0.15%   mixture of glycerides
 4-6% glycerol
 6-8%. A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.

公开(公告)号：US20220296541A1

公开(公告)日：2022-09-22

申请号：US17691572

申请日：2022-03-10

申请人： EPITECH GROUP S.P.A.

发明人： Francesco DELLA VALLE ,  Maria Federica DELLA VALLE ,  Chiara GOMERIO ,  Francesca BORRELLI ,  Raffaele CAPASSO ,  Angelo Antonio IZZO ,  Ester PAGANO ,  Barbara ROMANO

IPC分类号： A61K31/164 ,  A61K9/14 ,  A61K9/20 ,  A61K9/16 ,  A61K9/48 ,  A61K9/28 ,  A61K9/02 ,  A61K9/06 ,  A61P35/00

摘要： Described herein is a use of N-palmitoylethanolamide in the context of an antitumor therapy, in particular, a use of Palmitoylethanolamide in the prevention of colorectal carcinoma, adenomatous polyps, and/or pre-neoplastic ACF lesions. Also described herein are palmitoylethanolamide for use in the antineoplastic therapy of colorectal carcinoma, in which the palmitoylethanolamide exerts a selective antiproliferative action on tumor cells and not on healthy cells.

公开(公告)号：US20210169828A1

公开(公告)日：2021-06-10

申请号：US17173669

申请日：2021-02-11

申请人： Epitech Group S.P.A.

发明人： Francesco Della Valle ,  Maria Federica Della Valle ,  Salvatore Cuzzocrea

IPC分类号： A61K31/16 ,  A61K31/164 ,  A61K31/728

摘要： Described herein are pharmaceutical compositions containing Adelmidrol. In particular, the Adelmidrol is used in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals, more particularly in the treatment of articular chondropathies of mechanical, toxic, iatrogenic, degenerative origin, or associated with inflammatory phenomena mainly related to organs and tissues not belonging to the osteoarticular system; fibrogenesis of the articular cartilages; chronic inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis; Irritable Bowel Syndrome (IBS); diseases characterized by an abnormal fibrosis of the connective tissue, such as systemic sclerosis, particularly of the skin and lung; eye disorders characterized by angiogenesis, fibrosis, inflammation and oxidative stress.